Product demo with features, software and best-practices

Get interesting insights about ZEISS O-INSPECT duo in our demo recording.

Trögt för genterapi mot blödarsjuka – kan dumpas av bolaget

Roctavian, en genterapi mot blödarsjuka som sågs som ett medicinsk genombrott, har floppat kommersiellt. Nu planerar företaget bakom att avyttra läkemedlet från sin portfölj.

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

Nordic Regulatory experts: Improving biotech chances of Succ

Why is it that so many biotech companies fail? And what are the tools needed to change that fact?

One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.

A new international stem cell research centre has been created in Copenhagen

A new centre for stem cell research opened to the public in January. The Novo Nordisk Foundation backs the initiative with the ambition that the centre will advance new medical technology and ...

Göran Stiernstedt: “We are the world’s worst at continuity”

Failed investments in primary care, an unreasonable system with online doctors and a public failure at coordinating the healthcare IT system. Göran Stiernstedt ...

Tirzepatide approved for obesity by the FDA – to be branded as Zepbound

Diabetes drug tirzepatide has now also been approved in the US for treating obesity.

Decades of research destroyed at KI – a hacker attack cannot be ruled out!

Years of research, together with half a billion Swedish krona, went up in smoke when the freezers at Karolinska Institutet overheated. The breakdown has now bee...

Cleveland Clinic: Kirurgi gav fler långsiktiga fördelar än GLP-1-läkemedel

Metabol kirurgi minskade riskerna för död, hjärtsjukdom, njursvikt och ögonskador mer än GLP-1-läkemedel under en tioårsperiod. Det enligt en ny studie från Cle...

Study: Vaccination linked to lower risk of post-COVID

The risk of developing post-COVID after a COVID infection was reduced in vaccinated people, according to a new study from the University of Gothenburg.

Bioarctic granted Japanese patent for Parkinson’s disease candidate

Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.

Björn Ursing: Physicians new role in AI driven healthcare

”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians cha...

The pandemic caused a reshuffle among the world’s vaccine giants – here is the new top list

Fuelled by the pandemic, the power balance in the global vaccine market has completely changed in recent years, a survey from Fierce Pharma shows

EMA review confirms a risk of new cancer after CAR-T

CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...

The first Lyme disease vaccine faces a delay

Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the ...

Discover the new ZEISS Axioscan 7 clinical

Your digital slide scanner for diagnostics & clinical research.

TFS Trial Form Support AB

Collaboration for a simpler production of gene therapies launched

A collaboration between universities and companies aims at providing better production methods for the development of gene therapies. The initiative is led by J...

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

Sahlgrenska Science Park

Pharma Relations AB